Catherine Novack
Stock Analyst at JonesTrading
(4.64)
# 905
Out of 5,133 analysts
131
Total ratings
40.3%
Success rate
21.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Catherine Novack
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAPR Capricor Therapeutics | Reiterated: Hold | n/a | $9.53 | - | 12 | Sep 27, 2026 | |
| DTIL Precision BioSciences | Reiterated: Buy | $30 | $7.57 | +296.56% | 4 | Aug 7, 2026 | |
| WVE Wave Life Sciences | Reiterated: Buy | $35 → $30 | $3.13 | +858.47% | 15 | Aug 7, 2026 | |
| DARE Daré Bioscience | Rated: Hold | n/a | $0.6574 | - | 7 | Jul 31, 2026 | |
| EQ Equillium | Rated: Hold | n/a | $1.29 | - | 5 | Jul 31, 2026 | |
| FEMY Femasys | Rated: Hold | n/a | $1.42 | - | 9 | Jul 31, 2026 | |
| PRQR ProQR Therapeutics | Reiterated: Buy | $11 → $10 | $1.41 | +609.22% | 4 | Jun 26, 2026 | |
| SPRB Spruce Biosciences | Initiated Coverage: Buy | $135 | $43.31 | +211.71% | 1 | Jun 8, 2026 | |
| RZLT Rezolute | Reiterated: Buy | $6 | $3.66 | +64.16% | 9 | Jun 2, 2026 | |
| IBIO iBio, Inc. | Reiterated: Buy | $7 | $0.7317 | +856.68% | 2 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $23 | $13.61 | +68.99% | 3 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $15.72 | - | 10 | Apr 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.385 | - | 4 | Apr 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 → $13 | $3.02 | +330.46% | 9 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $143 → $209 | $152.48 | +37.07% | 7 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $43 | $42.60 | +0.94% | 1 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $33 | $1.33 | n/a | 1 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 → $9 | $0.6438 | n/a | 14 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $30 | $17.16 | n/a | 1 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $1.21 | n/a | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $160 → $60 | $1.63 | n/a | 4 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $4.31 | n/a | 4 | Nov 15, 2021 |
Capricor Therapeutics
Sep 27, 2026
Reiterated: Hold
Price Target: n/a
Current: $9.53
Upside: -
Precision BioSciences
Aug 7, 2026
Reiterated: Buy
Price Target: $30
Current: $7.57
Upside: +296.56%
Wave Life Sciences
Aug 7, 2026
Reiterated: Buy
Price Target: $35 → $30
Current: $3.13
Upside: +858.47%
Daré Bioscience
Jul 31, 2026
Rated: Hold
Price Target: n/a
Current: $0.6574
Upside: -
Equillium
Jul 31, 2026
Rated: Hold
Price Target: n/a
Current: $1.29
Upside: -
Femasys
Jul 31, 2026
Rated: Hold
Price Target: n/a
Current: $1.42
Upside: -
ProQR Therapeutics
Jun 26, 2026
Reiterated: Buy
Price Target: $11 → $10
Current: $1.41
Upside: +609.22%
Spruce Biosciences
Jun 8, 2026
Initiated Coverage: Buy
Price Target: $135
Current: $43.31
Upside: +211.71%
Rezolute
Jun 2, 2026
Reiterated: Buy
Price Target: $6
Current: $3.66
Upside: +64.16%
iBio, Inc.
May 13, 2026
Reiterated: Buy
Price Target: $7
Current: $0.7317
Upside: +856.68%
May 8, 2026
Upgraded: Buy
Price Target: $23
Current: $13.61
Upside: +68.99%
Apr 10, 2026
Rated: Hold
Price Target: n/a
Current: $15.72
Upside: -
Apr 10, 2026
Rated: Hold
Price Target: n/a
Current: $0.385
Upside: -
Feb 24, 2026
Reiterated: Buy
Price Target: $7 → $13
Current: $3.02
Upside: +330.46%
Feb 24, 2026
Reiterated: Buy
Price Target: $143 → $209
Current: $152.48
Upside: +37.07%
Dec 23, 2025
Initiated Coverage: Buy
Price Target: $43
Current: $42.60
Upside: +0.94%
Sep 30, 2025
Initiated Coverage: Buy
Price Target: $33
Current: $1.33
Upside: n/a
Aug 8, 2025
Reiterated: Buy
Price Target: $6 → $9
Current: $0.6438
Upside: n/a
Jun 25, 2025
Initiated Coverage: Buy
Price Target: $30
Current: $17.16
Upside: n/a
Nov 15, 2024
Reiterated: Buy
Price Target: $15
Current: $1.21
Upside: n/a
Jun 3, 2024
Reiterated: Buy
Price Target: $160 → $60
Current: $1.63
Upside: n/a
Nov 15, 2021
Downgraded: Hold
Price Target: n/a
Current: $4.31
Upside: n/a